Developer docs
API playgroundTry for free, no card

Search company profiles

Bryan, Garnier & Co

Full company profile

uuid0008s1f

Namestring
Bryan, Garnier & Co
Legal namestring
Bryan, Garnier & Co.
Company typeenum
Private
Founded yearint
1995
Descriptiontext

Bryan, Garnier & Co is a European independent investment bank founded in 1995 and headquartered in Paris, with an additional principal office in London. The firm focused on middle-market advisory in two core verticals — healthcare (including medtech and biopharma) and technology (including software and tech-enabled services) — serving corporate clients and institutional investors across Europe and, through trans-Atlantic execution capabilities, North America. Service lines spanned private buy-side and sell-side M&A, public takeovers and defense, strategic advisory, IPO advisory, rights issues, equity private placements, debt and equity capital markets, and equity research, sales and trading; pricing was transaction-based with success fees and multi-year corporate broking relationships (particularly on the UK Main Market and AIM). The firm pursued an active inorganic growth strategy, acquiring Cartagena Capital (2016), Beringer Finance (2019), Brocair Partners (2019), and NOR Capital (2023) prior to its own sale. On 2025-02-06, Stifel Financial Corp. completed the acquisition of Bryan, Garnier & Co, integrating the franchise into its European platform and reabsorbing its research and thought-leadership output into the Stifel IRIS content platform; the firm no longer operates as an independent entity.

Short descriptiontext

Bryan, Garnier & Co was a European middle-market investment bank specializing in healthcare and technology advisory. It provided M&A, capital markets, and equity research services to corporates and institutional investors across Europe and North America before its February 2025 acquisition by Stifel.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
investment banking services, mergers and acquisitions advisory, capital markets advisory, equity research sales, middle market advisory
Industry4 codes
PRIMARYFSAEAGAJ
Industry-Specialist / Sector-Focused M&A Advisory
SECONDARYBPAHAOAA
M&A Advisory (Buy-Side & Sell-Side)
SECONDARYFSAEAGAE
Corporate Finance Advisory (Strategic Finance, Capital Structure & Recaps)
SECONDARYFSAEAGAH
Cross-Border M&A Advisory
NAICS code2 codes
  • Investment Banking and Securities Intermediation52315
  • Securities, Commodity Contracts, and Other Financial Investments and Related Activities523
SIC code2 codes
  • Services-Engineering, Accounting, Research, Management8700
  • Services-Management Consulting Services8742
Product category
Investment Banking Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Investment Banking Advisory
TypeProfessional Services
Description

M&A advisory, strategic advisory, and transaction execution for middle-market companies in healthcare and technology verticals. Services include private buy-side and sell-side M&A, public takeovers, IPO advisory, rights issues, and equity private placements.

stifelinstitutional.com
2Capital Markets
TypeProfessional Services
Description

Debt and equity capital markets solutions including investment and sub-investment grade financings, and capital markets advisory.

stifelinstitutional.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Pricing details1 tier
1M&A Advisory Services
ModelOtherBilling cadenceMulti-year contract
Notes

Transaction-based fees typically structured as a percentage of deal value, with success fees common for completed transactions.

stifelinstitutional.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Bryan, Garnier & Co is a European middle-market investment bank that provides M&A advisory, capital markets solutions, equity research, and sales & trading services. The firm specializes in the healthcare and technology verticals, serving dynamic mid-market companies and institutional investors across Europe with trans-Atlantic advisory capabilities connecting European companies to North American capital markets.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Bryan, Garnier & Co was a European middle market investment bank specializing in the healthcare and technology verticals. The firm provided advisory services and was subsequently acquired by Stifel in February 2025. Post-acquisition, the firm operates as part of Stifel's European operations.

Product and service4 records
1Investment Banking Advisory
CategoryInvestment Banking
Description

Full-service investment banking advisory covering M&A (private buy-side and sell-side), public takeovers and defense, strategic advisory, investor positioning, IPOs, rights issues, and equity private placements. Serves mid-market healthcare and technology companies across Continental Europe, North America, the Middle East, and Asia.

2Capital Solutions
CategoryCapital Markets
Description

London-based Capital Solutions Group providing full range of public and private capital markets solutions including investment and sub-investment grade financings, complex and distressed situations, debt financing structures, restructuring and liability management. Leverages Stifel's global coverage of more than 8,000 accounts from large institutions to private wealth.

3UK Corporate Broking
CategoryCorporate Broking
Description

UK corporate broking service offering retained relationships with companies listed on the Main Market and AIM, providing equity capital markets support, M&A advice, defense advisory, and debt capital markets insight. Active across Healthcare, Technology, Financials, Real Estate, Energy and Resources, and Investment Funds sectors.

4Equity Research, Sales & Trading
CategoryEquity Research and Trading
Description

Pan-European equity research, sales and trading product providing forward-thinking research and analysis through articles, white papers, quarterly reports, and market insights via the Stifel IRIS platform, covering mid-cap companies for institutional investors.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

European-headquartered independent advisory firm with deep M&A and capital markets capabilities across mid-cap healthcare, technology, and industrials. Highly comparable business model and client base to Bryan Garnier.

TypeRegional player
Description

Italy-headquartered independent investment bank with strong European mid-cap M&A advisory and equity research franchises. Comparable European mid-market advisory positioning with sector-agnostic but adjacent verticals.

TypeDirect peer
Description

US-based middle-market investment bank with strong healthcare and technology sector practices. Comparable vertical-specialist mid-market positioning with cross-border capability similar to Bryan Garnier's trans-Atlantic focus.

TypeDirect peer
Description

Global independent investment bank with strong M&A advisory franchise and significant European mid-market healthcare and technology coverage. Direct competitor for sell-side and buy-side mandates in Bryan Garnier's core verticals.

TypeDirect peer
Description

Independent advisory-focused investment bank with strong M&A franchise in healthcare and technology. Comparable advisory-driven model and middle-to-upper-middle market positioning.

6Oakley Advisory
TypeEmerging player
Description

European independent advisory boutique with focus on mid-market M&A in healthcare, technology, and consumer. Smaller scale but directly comparable boutique advisory model and vertical focus.

TypeDirect peer
Description

Middle-market investment bank with significant European operations and dedicated healthcare and technology coverage. Competes for many of the same cross-border mid-cap advisory mandates as Bryan Garnier.

TypeEmerging player
Description

European independent advisory firm specializing in technology and digital media M&A. Niche player with comparable boutique focus on European tech mandates.

9DC Advisory
TypeDirect peer
Description

European-headquartered mid-market M&A advisor with sector specializations overlapping Bryan Garnier's healthcare and technology verticals. Closely comparable boutique advisory model.

TypeBroad incumbent
Description

UK mid-market investment bank acquired by Deutsche Bank, with strong healthcare and technology sector coverage in UK and European mid-caps. Recently transitioned from independent to incumbent platform, mirroring Bryan Garnier's Stifel path.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bryan, Garnier & Co

Investment Banking Servicesbryangarnier.com

Bryan, Garnier & Co was a European middle-market investment bank specializing in healthcare and technology advisory. It provided M&A, capital markets, and equity research services to corporates and institutional investors across Europe and North America before its February 2025 acquisition by Stifel.

What Bryan, Garnier & Co does

Bryan, Garnier & Co is a European independent investment bank founded in 1995 and headquartered in Paris, with an additional principal office in London. The firm focused on middle-market advisory in two core verticals — healthcare (including medtech and biopharma) and technology (including software and tech-enabled services) — serving corporate clients and institutional investors across Europe and, through trans-Atlantic execution capabilities, North America. Service lines spanned private buy-side and sell-side M&A, public takeovers and defense, strategic advisory, IPO advisory, rights issues, equity private placements, debt and equity capital markets, and equity research, sales and trading; pricing was transaction-based with success fees and multi-year corporate broking relationships (particularly on the UK Main Market and AIM). The firm pursued an active inorganic growth strategy, acquiring Cartagena Capital (2016), Beringer Finance (2019), Brocair Partners (2019), and NOR Capital (2023) prior to its own sale. On 2025-02-06, Stifel Financial Corp. completed the acquisition of Bryan, Garnier & Co, integrating the franchise into its European platform and reabsorbing its research and thought-leadership output into the Stifel IRIS content platform; the firm no longer operates as an independent entity.

Bryan, Garnier & Co firmographics

Firmographics
Name
Bryan, Garnier & Co
Legal name
Bryan, Garnier & Co.
Website
https://bryangarnier.com
Company type
Private
Founded year
1995
Operating status
Acquired
Headcount range
251–500 employees
Short description
Bryan, Garnier & Co was a European middle-market investment bank specializing in healthcare and technology advisory. It provided M&A, capital markets, and equity research services to corporates and institutional investors across Europe and North America before its February 2025 acquisition by Stifel.
Ownership category
akta.pro rank

Bryan, Garnier & Co industry classification

Industry
Product category
Investment Banking Services
NAICS
Investment Banking and Securities Intermediation (52315), Securities, Commodity Contracts, and Other Financial Investments and Related Activities (523)
SIC
Services-Engineering, Accounting, Research, Management (8700), Services-Management Consulting Services (8742)
akta.pro industry
PRIMARYFSAEAGAJ
Industry-Specialist / Sector-Focused M&A Advisory
SECONDARYBPAHAOAA
M&A Advisory (Buy-Side & Sell-Side)
SECONDARYFSAEAGAE
Corporate Finance Advisory (Strategic Finance, Capital Structure & Recaps)
SECONDARYFSAEAGAH
Cross-Border M&A Advisory

Keywords

  • Investment banking services
  • Mergers and acquisitions advisory
  • Capital markets advisory
  • Equity research sales
  • Middle market advisory

Where Bryan, Garnier & Co is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Bryan, Garnier & Co business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Investment Banking Advisory: M&A advisory, strategic advisory, and transaction execution for middle-market companies in healthcare and technology verticals. Services include private buy-side and sell-side M&A, public takeovers, IPO advisory, rights issues, and equity private placements.
  2. Capital Markets: Debt and equity capital markets solutions including investment and sub-investment grade financings, and capital markets advisory.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractM&A Advisory Services

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Bryan, Garnier & Co product offering

Product offering

Core offering

Bryan, Garnier & Co is a European middle-market investment bank that provides M&A advisory, capital markets solutions, equity research, and sales & trading services. The firm specializes in the healthcare and technology verticals, serving dynamic mid-market companies and institutional investors across Europe with trans-Atlantic advisory capabilities connecting European companies to North American capital markets.

Product overview

Bryan, Garnier & Co was a European middle market investment bank specializing in the healthcare and technology verticals. The firm provided advisory services and was subsequently acquired by Stifel in February 2025. Post-acquisition, the firm operates as part of Stifel's European operations.

Differentiator

Problem solved

Functional benefit

Products and services

  • Investment Banking Advisory Full-service investment banking advisory covering M&A (private buy-side and sell-side), public takeovers and defense, strategic advisory, investor positioning, IPOs, rights issues, and equity private placements. Serves mid-market healthcare and technology companies across Continental Europe, North America, the Middle East, and Asia.
  • Capital Solutions London-based Capital Solutions Group providing full range of public and private capital markets solutions including investment and sub-investment grade financings, complex and distressed situations, debt financing structures, restructuring and liability management. Leverages Stifel's global coverage of more than 8,000 accounts from large institutions to private wealth.
  • UK Corporate Broking UK corporate broking service offering retained relationships with companies listed on the Main Market and AIM, providing equity capital markets support, M&A advice, defense advisory, and debt capital markets insight. Active across Healthcare, Technology, Financials, Real Estate, Energy and Resources, and Investment Funds sectors.
  • Equity Research, Sales & Trading Pan-European equity research, sales and trading product providing forward-thinking research and analysis through articles, white papers, quarterly reports, and market insights via the Stifel IRIS platform, covering mid-cap companies for institutional investors.

Companies that use Bryan, Garnier & Co

Customer profile

Segments3 records

Ideal customer profiles3 records

Bryan, Garnier & Co technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Bryan, Garnier & Co partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Bryan, Garnier & Co competitors and assessment

Company assessment

Direct peers

  • Rothschild & Co: European-headquartered independent advisory firm with deep M&A and capital markets capabilities across mid-cap healthcare, technology, and industrials. Highly comparable business model and client base to Bryan Garnier.
  • William Blair: US-based middle-market investment bank with strong healthcare and technology sector practices. Comparable vertical-specialist mid-market positioning with cross-border capability similar to Bryan Garnier's trans-Atlantic focus.
  • Lazard: Global independent investment bank with strong M&A advisory franchise and significant European mid-market healthcare and technology coverage. Direct competitor for sell-side and buy-side mandates in Bryan Garnier's core verticals.
  • Evercore: Independent advisory-focused investment bank with strong M&A franchise in healthcare and technology. Comparable advisory-driven model and middle-to-upper-middle market positioning.
  • Jefferies: Middle-market investment bank with significant European operations and dedicated healthcare and technology coverage. Competes for many of the same cross-border mid-cap advisory mandates as Bryan Garnier.
  • DC Advisory: European-headquartered mid-market M&A advisor with sector specializations overlapping Bryan Garnier's healthcare and technology verticals. Closely comparable boutique advisory model.

Regional players

  • Mediobanca: Italy-headquartered independent investment bank with strong European mid-cap M&A advisory and equity research franchises. Comparable European mid-market advisory positioning with sector-agnostic but adjacent verticals.

Emerging players

  • Oakley Advisory: European independent advisory boutique with focus on mid-market M&A in healthcare, technology, and consumer. Smaller scale but directly comparable boutique advisory model and vertical focus.
  • Arma Partners: European independent advisory firm specializing in technology and digital media M&A. Niche player with comparable boutique focus on European tech mandates.

Broad incumbents

  • Numis (Deutsche Bank): UK mid-market investment bank acquired by Deutsche Bank, with strong healthcare and technology sector coverage in UK and European mid-caps. Recently transitioned from independent to incumbent platform, mirroring Bryan Garnier's Stifel path.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Bryan, Garnier & Co social profiles

Digital presence

Bryan, Garnier & Co financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bryan, Garnier & Co leadership team

Management profile

Number of profiles

Profiles4 records

Bryan, Garnier & Co funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bryan, Garnier & Co M&A and investment

M&A and investment

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bryan, Garnier & Co

What does Bryan, Garnier & Co do?

Bryan, Garnier & Co is a European middle-market investment bank that provides M&A advisory, capital markets solutions, equity research, and sales & trading services. The firm specializes in the healthcare and technology verticals, serving dynamic mid-market companies and institutional investors across Europe with trans-Atlantic advisory capabilities connecting European companies to North American capital markets.

Is Bryan, Garnier & Co a public or private company?

Bryan, Garnier & Co is a private company. It is classified as corporate owned and is currently acquired.

When was Bryan, Garnier & Co founded?

Bryan, Garnier & Co was founded in 1995. It employs 251 to 500 people.

Where is Bryan, Garnier & Co based?

Bryan, Garnier & Co is headquartered in London, United Kingdom, in the Europe region.

How does Bryan, Garnier & Co make money?

Two revenue lines are on record. Investment Banking Advisory is the primary driver. The others are capital Markets.

Who are Bryan, Garnier & Co's main competitors?

Direct peers on record are Rothschild & Co, William Blair, Lazard, Evercore, Jefferies and DC Advisory. Mediobanca is listed as a regional player. Emerging players are Oakley Advisory and Arma Partners. Numis (Deutsche Bank) is listed as a broad incumbent.

Does Bryan, Garnier & Co have an API?

No public API is recorded for Bryan, Garnier & Co.

What industry is Bryan, Garnier & Co in?

Bryan, Garnier & Co's product category is Investment Banking Services. Its primary akta.pro industry code is FSAEAGAJ, Industry-Specialist / Sector-Focused M&A Advisory, with a secondary code of BPAHAOAA, M&A Advisory (Buy-Side & Sell-Side). Its NAICS code is 52315 and its SIC code is 8700.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Stifel: Acquisition Of Bryan, Garnier & Co. AnnouncedStifel Financial agreed to acquire Bryan, Garnier & Co., a European investment bank focused on technology and healthcare. The deal terms were undisclosed, and Bryan Garnier has about 200 professionals across multiple offices. Stifel is on pace to generate over $4.8 billion in net revenue in 2024.GlobeNewswireStifel Announces Acquisition of Bryan, Garnier & Co.Stifel Financial Corp. signed a definitive agreement to acquire Bryan, Garnier & Co., a European investment bank focused on healthcare and technology. Terms were not disclosed, and Bryan Garnier has about 200 employees. The deal is expected to complement Stifel's global advisory business.GlobeNewswireStifel Announces Acquisition of Bryan, Garnier & Co.Stifel Financial Corp. signed a definitive agreement to acquire Bryan, Garnier & Co., a European investment bank focused on healthcare and technology. Terms were not disclosed, but Stifel is on pace to generate over $4.8 billion in net revenue in 2024.MarketScreenerPraise from Bryan Garnier boosts Fielmann and Mister SpexBryan Garnier's positive analyst commentary boosted Fielmann and Mister Spex on Friday. Fielmann shares rose 3.7% to 43.55 euros, while Mister Spex gained 5.83% to 2.54 euros. The analyst rates both as buy with target prices of 58 and 7 euros, respectively.GlobeNewswireBryan Garnier & Co Initiates the Coverage of Quantum Genomics with a Target Price at 13€ per ShareBryan Garnier & Co initiated coverage of Quantum Genomics with a buy recommendation and a 13€ per share target, valuing the company at 450M€. The target is set before the company's FRESH phase III study presentation at the American Heart Association in November 2022.GlobeNewswireValneva Announces an Indicative Price Range of its Previously Announced Proposed Global OfferingValneva announced an indicative price range of EUR 10-12 per ordinary share for its global offering, equivalent to USD 24.04-28.85 per ADS. The price will be at least the volume-weighted average price of its shares on Euronext Paris over 3-90 trading days, reduced by up to 15%. Goldman Sachs, Jefferies, Guggenheim, and Bryan, Garnier & Co. are joint bookrunners.news.cision.comTargovax to present at Bryan Garnier & Co Virtual European Healthcare ConferenceTargovax management will present the company at Bryan Garnier & Co's Virtual European Healthcare Conference on 17 November. The presentation will be available for download at targovax.com after the event. Targovax is a clinical-stage immuno-oncology company developing immune activators for solid tumors, with its lead product candidate ONCOS-102 in mesothelioma, melanoma, and colorectal cancer.GlobeNewswireZealand Pharma to participate in upcoming investor conferencesZealand Pharma announced that senior management will participate virtually in three investor conferences in November: Bryan, Garnier & Co, Jefferies, and Nordea. The company, a biotech focused on peptide-based medicines, will also host a live webcast of the Jefferies event.BloombergBankers Are Circling Europe’s Growing Cannabis MarketInvestment bankers are increasing coverage of European cannabis companies, with Canaccord Genuity appointing a head of European cannabis investment banking. French bank Bryan Garnier & Co. and Jefferies Financial Group have also started covering the sector, signaling growing interest as European pot businesses grow.GlobeNewswireBryan Garnier & Co Initiates Coverage of Onxeo with a “Buy” RecommendationBryan Garnier & Co initiated coverage of Onxeo with a Buy recommendation, valuing the company at 1.22 euros per share. The firm will now follow Onxeo's share price on Euronext Paris. Onxeo is a clinical-stage biotechnology company developing DNA damage response inhibitors for rare or resistant cancers.